PRESERVE, N = 594 | PRIZE, N = 192 | T2T, N = 331 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sustained deep remission n = 133 (22%) | Deep remission n = 136 (23%) | Sustained remission n = 96 (16%) | Remission n = 116 (20%) | LDA n = 113 (19%) | Sustained deep remission n = 67 (35%) | Deep remission n = 40 (21%) | Sustained remission n = 39 (20%) | Remission n = 46 (24%) | Sustained deep remission n = 13 (4%) | Deep remission n = 30 (9%) | Sustained remission n = 10 (3%) | Remission n = 70 (21%) | LDA n = 208 (63%) | |
Demographic characteristics | ||||||||||||||
Age, years, mean (SD) | 43.6 (12.6) | 47.9 (12.1) | 47.1 (12.0) | 47.9 (12.3) | 51.8 (10.3)*** | 43.7 (14.4) | 54.1 (13.7) | 49.7 (13.3) | 53.3 (13.7)** | 41.1 (13.5) | 44.4 (14.4) | 52.3 (11.5) | 44.3 (11.7) | 47.8 (12.1)* |
Female, n (%) | 97 (73) | 111 (82) | 82 (85) | 98 (84) | 91 (81) | 41 (61) | 27 (68) | 25 (64) | 31 (67) | 9 (69) | 22 (73) | 9 (90) | 57 (81) | 182 (88)* |
BMI, kg/m2, mean (SD) | 25.0 (3.9) | 25.5 (4.2) | 25.8 (5.3) | 25.2 (4.3) | 26.4 (5.1) | 24.4 (3.5) | 26.5 (4.9) | 26.3 (5.0) | 26.8 (5.0)** | 24.4 (4.6) | 26.5 (4.7) | 23.6 (3.1) | 28.4 (5.9) | 26.8 (5.3) |
BMI, female | 24.6 (3.8) | 25.3 (4.3) | 25.8 (5.4) | 24.9 (4.3) | 26.7 (5.2)* | 23.2 (3.4) | 25.5 (4.6) | 25.7 (4.4) | 25.6 (4.9)* | 25.0 (4.6) | 26.7 (5.0) | 23.5 (3.2) | 28.4 (6.0) | 26.7 (5.4) |
BMI, male | 26.3 (4.2) | 26.1 (3.8) | 25.9 (4.9) | 26.7 (4.3) | 25.4 (4.6) | 26.2 (3.1) | 28.7 (4.8) | 27.5 (5.9) | 29.1 (4.3) | 23.2 (5.1) | 26.0 (3.8) | 24.6 | 28.5 (5.8) | 27.3 (4.9) |
Prior treatmenta | ||||||||||||||
Corticosteroid(s), n (%) | 76 (57) | 76 (56) | 56 (58) | 77 (66) | 70 (62) | 22 (33) | 18 (45) | 17 (44) | 22 (48) | 9 (69) | 17 (57) | 6 (60) | 52 (74) | 140 (67) |
NSAID(s), n (%) | 98 (74) | 103 (76) | 68 (71) | 91 (78) | 85 (75) | 47 (70) | 27 (68) | 27 (69) | 29 (63) | 11 (85) | 19 (63) | 6 (60) | 40 (57) | 144 (69) |
DMARD(s),b n (%) | 37 (28) | 41 (30) | 18 (19) | 29 (25) | 23 (20) | 11 (16) | 11 (28) | 5 (13) | 6 (13) | 4 (31) | 10 (33) | 2 (20) | 38 (54) | 65 (31) |
Number of DMARD(s)b,c mean (min, max) | 1.3 (1, 3) | 1.3 (1, 3) | 1.2 (1, 3) | 1.3 (1, 5) | 1.2 (1, 2) | 1.0 (1, 1) | 1.0 (1, 1) | 1.0 (1, 1) | 1.0 (1, 1) | 1.3 (1, 2) | 1.3 (1, 2) | 1.0 (1, 1) | 1.5 (1, 3) | 1.3 (1, 3) |
Disease characteristics | ||||||||||||||
Duration of disease, mean (SD) | 6.3 (6.8) years | 6.6 (6.2) years | 7.3 (6.5) years | 7.3 (7.7) years | 6.7 (7.1) years | 6.7 (2.8) months | 7.4 (3.2) months | 6.3 (2.6) months | 7.0 (3.0) months | 7.9 (6.2) years | 6.3 (5.6) years | 8.0 (4.8) years | 8.3 (6.8) years | 8.4 (7.5) years |
RF+, n (%) | 96 (72) | 94 (69) | 77 (80) | 84 (72) | 78 (69) | 44 (66) | 25 (63) | 18 (46) | 24 (52) | 9 (69) | 23 (77) | 9 (90) | 59 (84) | 175 (84) |
aCCP antibody+, n (%) | 100 (75) | 99 (73) | 82 (85) | 99 (85) | 85 (75) | 47 (70) | 27 (68) | 23 (59) | 29 (63) | 9 (69) | 24 (80) | 10 (100) | 49 (70) | 171 (82) |
ESR, mm/h, mean (SD) | 17.9 (10.6) | 20.8 (13.0) | 24.4 (12.9) | 22.7 (11.8) | 22.1 (13.9)** | 30.1 (22.3) | 36.3 (24.3) | 38.4 (20.6) | 31.7 (19.1) | 25.5 (13.8) | 37.6 (21.7) | 32.1 (15.1) | 43.7 (27.7) | 50.8 (24.7)*** |
CRP, mg/L, mean (SD) | 10.7 (13.8) | 10.5 (12.1) | 11.4 (14.2) | 11.8 (14.7) | 14.2 (20.4) | 13.4 (18.6) | 19.8 (27.1) | 16.3 (24.3) | 13.8 (16.6) | 21.5 (18.2) | 22.0 (16.7) | 14.9 (11.9) | 21.1 (19.9) | 24.0 (29.3) |
Disease activity and patient-reported outcomes, mean (SD) | ||||||||||||||
TJC (0–28) | 4.9 (2.8) | 5.2 (2.4) | 4.7 (2.8) | 4.8 (2.8) | 5.5 (3.5) | 12.5 (5.8) | 13.3 (6.8) | 13.4 (6.8) | 14.3 (7.2) | 10.1 (6.6) | 12.3 (6.7) | 13.7 (6.4) | 14.1 (6.7) | 14.3 (6.1)* |
SJC (0–28) | 3.9 (2.7) | 3.8 (2.5) | 4.0 (2.7) | 3.6 (2.4) | 4.4 (3.1) | 8.8 (5.0) | 11.0 (6.0) | 11.1 (6.3) | 11.0 (5.2)* | 9.5 (5.4) | 9.9 (5.9) | 10.5 (5.5) | 10.7 (5.4) | 10.6 (5.5) |
DAS28-ESR, mean (SD) | 4.2 (0.5) | 4.3 (0.4) | 4.4 (0.4) | 4.4 (0.4) | 4.4 (0.5)*** | 5.6 (1.0) | 6.0 (1.1) | 6.0 (1.1) | 5.9 (1.1) | 5.5 (1.3) | 6.0 (1.2) | 6.1 (0.9) | 6.3 (1.1) | 6.5 (0.9)*** |
CDAI (0–76) | 17.8 (4.9) | 17.4 (4.6) | 17.3 (5.2) | 17.5 (4.6) | 18.9 (5.6) | – | – | – | – | 31.2 (15.0) | 35.3 (12.5) | 38.1 (11.0) | 38.6 (12.7) | 38.3 (11.4)* |
PGA (0–10) | 4.1 (1.4) | 3.9 (1.3) | 4.0 (1.3) | 4.2 (1.3) | 4.1 (1.2) | 5.2 (1.6) | 5.8 (1.5) | 5.8 (1.8) | 5.5 (1.5) | 6.1 (1.7) | 6.8 (1.3) | 7.2 (1.0) | 6.9 (1.6) | 6.7 (1.3) |
HAQ (0–3) | 0.9 (0.5) | 1.2 (0.6) | 1.1 (0.5) | 1.1 (0.6) | 1.2 (0.5)* | 1.1 (0.5) | 1.3 (0.6) | 1.2 (0.7) | 1.1 (0.7) | 1.0 (0.8) | 1.3 (0.6) | 1.3 (0.7) | 1.6 (0.7) | 1.5 (0.6)** |